Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP LossNeoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Thoracic Neoplasms, astrocytoma (excluding glioblastoma), brain disorder, bronchial neoplasm, bronchogenic carcinoma, central nervous system cancer, central nervous system disorder, epithelial neoplasm, glioblastoma, glioma, lung cancer, lung disorder, lung neoplasm, malignant glioma, neoplasm, nervous system disorder, neuroepithelial neoplasm, non-small cell lung carcinoma, primitive neuroectodermal tumor, respiratory system disorder, respiratory tract neoplasmRecruitingPhase 1 / Phase 22026-04-13NCT06810544

2 results · Page 1 of 1

Swipe the table sideways for more columns.

OrganizationsLinked trials
Eli Lilly and Company370
Tango Therapeutics, Inc.5

15 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sitesCityCountryLinked trials
Dana Farber Cancer InstituteBostonUnited States300
Mayo Clinic Cancer CenterRochesterUnited States2
Mayo Clinic JacksonvilleJacksonvilleUnited States67
Mayo Clinic ScottsdaleScottsdaleUnited States2
MD Anderson Cancer CenterHoustonUnited States589
Memorial Sloan Kettering Cancer CenterNew YorkUnited States3
NEXT VirginiaFairfaxUnited States83
Northwestern Memorial HospitalChicagoUnited States4
NYU Langone HealthNew YorkUnited States403
Ohio State University Comprehensive Cancer CenterColumbusUnited States548
Sibley Memorial HospitalWashington D.C.United States121
University of California at San FranciscoSan FranciscoUnited States1
University of California Los AngelesLos AngelesUnited States1
University of California, IrvineIrvineUnited States1
University of Utah, Huntsman Cancer InstituteSalt Lake CityUnited States1